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180 (135–219) min after methadone intake. QTc did not increase 
with increasing methadone concentrations, R2 = 0.0015.
Conclusion: Another route than renal and hemodialysis must 
eliminate methadone in these patients as only a small amount of 
methadone was lost in hemodialysate and urine. All values of serum-
methadone were comparable with those seen in patients with nor-
mal renal function after similar daily methadone doses. QTc tended 
to increase during hemodialysis. However, this increase was not 
concentration-dependent on methadone.
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Introduction: Different pharmaceutical formulations of the car-
diovascular drug, calcium antagonist, diltiazem may reflect in its 
different bioavailability, that may subsequently influence the pharma-
cological effects. The primary purpose of the study was to compare 
the cardiovascular activities of 2 different modified-release formula-
tions of diltiazem: gelatine capsules with micropellets and film-coated 
tablets. Secondary, we would like to consider if the pharmacodynamic 
data may be useful in concluding the therapeutic equivalence of dif-
ferent diltiazem formulations.
Patients (or Materials) and Methods: The study was conducted on 
a group of healthy, male subjects that participated in a randomized, 
2-way cross-over bioavailability trial of 2 diltiazem MR formulation 
after single and multiple doses of 120 mg. During the course of the 
study standard bioavailability parameters (AUCt, AUCinf, Cmax, 
Cmin) for both formulations were calculated. Bioequivalence tasting 
was based on Shuirmann’s procedure. Pharmacological effects were 
evaluated after single- and multiple-dose administration. Blood pres-
sure, ECG parameters (QTc, PQ) and heart rate variability (HRV) 
were measured continuously (ECG Holter monitoring) up to 24 
hours after administration and analyzed at the same time points as 
pharmacokinetic samples to plot the effect-time profile. Classical 
HRV analysis in time and frequency domains was conducted and 
several components of HRV estimated (RR, RMS, SDNN, PNN, 
LF, HF and LF/HF). Mean values at each time point and calculated 
effect parameters (AUEC, Emax, TEmax) were compared statistically 
between formulations (t-test, p< 0.05). Pharmacological data were 
correlated with pharmacokinetic parameters.
Results: Bioavailability analysis concluded inequivalence (CI for 
Cmax(single): 0.78–0.95). In pharmacodynamic analysis the only 
statistically significant difference was observed after multiple doses of 
diltiazem for the extend of PQ effect (AUEC0-8 [ms*h]; P = 0.0289). 
Differences for the other calculated BP, ECG and HRV parameters were 
statistically insignificant (p ≥ 0.05), although distinct diversity have 
been observed. Bioequivalence couldn’t be concluded in the basis of 
PD data. High variability of values was observed (CV% > 50%–60%).
Conclusion: Differences in the most of tested pharmacodynamic 
parameters were found between 2 diltiazem formulations. Although 
most of them were statistically insignificant they may indicate the 
diversity of 2 tested modified-release oral diltiazem formulations in 
respect of bioavailability and pharmacodynamics. Because of their 
high variability cardiovascular parameters can be used in the estima-
tion of therapeutic equivalence only in limited range.
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Introduction: The objectives of this study were to determine the 
pharmacokinetics (PK) and safety of single-dose sugammadex (16 
mg/kg) in healthy Chinese adult volunteers. The 16-mg/kg dose was 
chosen because this is the highest recommended dose for use in clini-
cal practice, for immediate reversal of NMB.
Patients (or Materials) and Methods: In this open-label study, 
healthy Chinese subjects received intravenous (IV) sugammadex 
(16 mg/kg) as a 10-second bolus infusion. Blood samples were 
collected pre-sugammadex and at regular intervals up to 24 hours 
post-sugammadex for PK assessment. Safety was also evaluated, 
via adverse events (AEs), vital signs, ECG, and laboratory param-
eters.
Results: Twelve subjects were included (6 male; 6 female). 
Geometric mean (CV%) weight was 58.3 (3.7%) kg and 53.6 
(9.8%) kg for males and females, respectively. The main pharma-
cokinetic parameters are shown in the Table. After the 16-mg/kg 
sugammadex dose, plasma sugammadex concentrations showed 
a polyexponential decline over time, indicating 2 to 3 compart-
ments, with an overall geometric mean (CV) terminal half-life 
(t½) of 145 (17.9%) minutes (139 [17.7%]) minutes for males; 
152 [18.6%] minutes for females). No influence of gender on the 
PK of sugammadex was observed. Three subjects experienced an 
AE (dysgeusia of mild intensity in all cases), which was consid-
ered possibly or probably related to sugammadex. Dysgeusia is 
a known adverse drug reaction in healthy conscious subjects. 
There were no clinically significant changes in vital signs, ECG, 
or laboratory parameters.
Conclusion: After a single IV bolus infusion dose of sugammadex 16 
mg/kg in healthy Chinese subjects, peak sugammadex concentration 
was 197 μ g/mL, clearance was 99.7 mL/min, and volume of distribu-
tion was 10.5 L. No influence of gender on the PK of sugammadex 
was observed. Overall between-subject variability on clearance and 
volume of distribution was ~10%. Sugammadex was generally well 
tolerated in Chinese volunteers.
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Table.  Geometric mean (CV %) pharmacokinetic parameters for 
sugammadex 16 mg/kg in Chinese subjects.
male (n = 6) Female (n = 6) Total (n = 12)
Tmax, min
a> 2.0 (2.0–3.0) Tmax, mina 3.0 (2.0–3.0) Tmax, mina 2.5 (2.0–3.0)
Cmax, µg/mL 214 (27.7%) Cmax, µg/mL 182 (10.6%) Cmax, µg/mL 197 (21.7%)
CL, mL/min 104 (12.5%) CL, mL/min 95.8 (12.4%) CL, mL/min 99.7 (12.6%)
Vss, L 10.7 (10.7%) Vss, L 10.3 (7.4%) Vss, L 10.5 (9.0%)
aValues given as median (range). Tmax = time to maximum observed concentration;  
Cmax = maximum observed concentration; CL = clearance, Vss = volume of distribution 
at equilibrium.
